Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS

about

Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS

Item

http://www.wikidata.org/entity/Q58780881

description

im August 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 20 July 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Low-dose onabotulinumtoxinA im ...... catheterizing patients with MS

@en

Low-dose onabotulinumtoxinA im ...... catheterizing patients with MS

@nl

type

Item

label

Low-dose onabotulinumtoxinA im ...... catheterizing patients with MS

@en

Low-dose onabotulinumtoxinA im ...... catheterizing patients with MS

@nl

prefLabel

Low-dose onabotulinumtoxinA im ...... catheterizing patients with MS

@en

Low-dose onabotulinumtoxinA im ...... catheterizing patients with MS

@nl

P1476

Low-dose onabotulinumtoxinA im ...... catheterizing patients with MS

@en

P2093

Alfred Kohan

http://www.w3.org/2001/XMLSchema#string

Blair Egerdie

http://www.w3.org/2001/XMLSchema#string

Brenda Jenkins

http://www.w3.org/2001/XMLSchema#string

Emmanuel Chartier-Kastler

http://www.w3.org/2001/XMLSchema#string

Jean Paul Nicandro

http://www.w3.org/2001/XMLSchema#string

Mark Tullman

http://www.w3.org/2001/XMLSchema#string

Meryl Mandle

http://www.w3.org/2001/XMLSchema#string

Pierre Denys

http://www.w3.org/2001/XMLSchema#string

Veronique Keppenne

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis

Neuromodulation in neurogenic bladder

Botulinum toxin type A products are not interchangeable: a review of the evidence.

Lower urinary tract symptom prevalence and management among patients with multiple sclerosis

The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines.

OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology

A UK consensus on the management of the bladder in multiple sclerosis.

EAU guidelines on neurogenic lower urinary tract dysfunction.

Management of neurogenic bladder in patients with multiple sclerosis.

P304

e657-e665

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0000000000005991

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Benjamin M Brucker

P577

2018-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30030330

http://www.w3.org/2001/XMLSchema#string

P932

6105039

http://www.w3.org/2001/XMLSchema#string